Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent

Swedish Firm Reveals Further Phase III Data For Proposed Lucentis Biosimilar

Executive Summary

With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.

You may also be interested in...



Xbrane Reveals Ranibizumab Refiling Plans For US

Xbrane has set out its plans to resubmit its application for a biosimilar rival to Lucentis in the US, after receiving details from the FDA on additional information needed for the agency to accept the BLA for review.

Xbrane Gets US Setback For Ranibizumab Filing

Xbrane Biopharma has withdrawn the BLA for its proposed Xlucane ranibizumab biosimilar rival to Lucentis in the US after the FDA said further information was required for it to accept the filing. Development partner Stada said it would “work closely” with Xbrane and US licensee Bausch + Lomb to get the product to market.

Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel